Tafolecimab + Sintilimab (approved) + Etoposide + Carboplatin / Cisplatin
Phase 2RecruitingDevelopment Stage
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer
Aug 1, 2025 → Aug 1, 2027
About Tafolecimab + Sintilimab (approved) + Etoposide + Carboplatin / Cisplatin
Tafolecimab + Sintilimab (approved) + Etoposide + Carboplatin / Cisplatin is a phase 2 stage product being developed by Innovent Biologics for Extensive-stage Small Cell Lung Cancer (ES-SCLC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07061535. Target conditions include Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07061535 | Phase 2 | Recruiting |
Competing Products
20 competing products in Extensive-stage Small Cell Lung Cancer (ES-SCLC)